INVO Fertility, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Fertility, Inc. (Nasdaq: IVF) on July 1, 2025, covering events occurring on June 26, 27, and 30, 2025. The filing details material amendments to debt and equity agreements, the exercise of investment rights by an institutional holder, and changes to the Company's capital structure regarding Series C-2 Convertible Preferred Stock.
Key Financial Metrics and Capital Structure
The filing does not provide standard financial performance metrics such as revenue, net income, operating cash flow, or liquidity ratios. Instead, it focuses on specific capital transactions:
- Debt-to-Equity Exchange: An institutional holder exchanged $1,800,000 in principal plus accrued interest of a Senior Secured Convertible Debenture (due Feb 2026) for 1,800 shares of Series C-2 Preferred Stock.
- Cash Investment: The same holder purchased 500 shares of Series C-2 Preferred Stock for $500,000 in cash.
- Reload Issuance: The Company issued 630 new shares of unregistered Series C-2 Preferred Stock to the holder as part of an inducement agreement.
- Conversion Price: Following the cash exercise, the conversion price for Series C-2 Preferred adjusted to $0.95 per share.
- Dividend Rate: Series C-2 Preferred accrues dividends at 10% per annum on the stated value.
Material Changes Versus Prior Period
The filing reports significant structural changes to the Company's financing arrangements compared to the prior state:
- Amendment to Purchase Agreement: The Securities Purchase Agreement was amended to allow the holder to exercise Additional Investment Rights (AIR) via cash purchase or by exchanging the Debenture for preferred shares. The minimum exercise amount for AIR was reduced from $500,000 to $200,000.
- Capital Structure Adjustment: The Company filed a Certificate of Amendment authorizing 20,000 shares of Series C-2 Preferred Stock with a stated value of $1,000 per share.
- Issuance Restrictions: The Company agreed to a 30-day moratorium on issuing common stock or equivalents and a one-year prohibition on "Variable Rate Transactions" (e.g., equity lines of credit or resettable conversion prices).
Guidance, Outlook, and Risks
The filing contains no specific financial guidance or revenue outlook. Management commentary is limited to the mechanics of the transactions and standard forward-looking statement disclaimers.
- Key Risk: The Company explicitly notes the risk regarding its ability to regain compliance with Nasdaq Listing Standards and maintain its listing.
- Contingencies: Conversion of Series C-2 Preferred into common stock is contingent upon stockholder approval. Additionally, conversions are subject to a 9.99% beneficial ownership limitation for the holder.
- Liquidation Preference: In a liquidation event, Series C-2 holders are entitled to the greater of 125% of the conversion amount or the as-converted common stock value.
Investor Verification Checklist
- Verify the current status of the Company's compliance with Nasdaq Listing Standards.
- Confirm the total outstanding principal of the Senior Secured Convertible Debenture and the remaining amount after the $1.8 million exchange.
- Review the specific terms of the "Variable Rate Transaction" prohibition to understand future financing constraints.
- Assess the dilution impact of the 20,000 authorized Series C-2 shares and the 10% annual dividend accrual on future cash flows.
- Check for any pending stockholder votes required to enable the conversion of Series C-2 Preferred into common stock.